期刊
ACS CHEMICAL NEUROSCIENCE
卷 12, 期 4, 页码 581-588出版社
AMER CHEMICAL SOC
DOI: 10.1021/acschemneuro.0c00629
关键词
BACE1; BACE2; selective inhibitors; Alzheimer's disease; type II diabetes; structure-based drug design
资金
- National Institutes of Health [AG 18933, 5U54AG065181]
- Purdue EVPRP
- NIH [P30 CA023168]
This study developed a platform to produce large amounts of pure BACE2 protein and designed compounds that selectively inhibit BACE1 over BACE2. The research findings could lead to the quicker development of new selective BACE inhibitors for treating Alzheimer's disease or type II diabetes.
The ability to perform routine structure-guided drug design for selective BACE inhibitors has been limited because of the lack of robust platform for BACE2 expression, purification, and crystallization. To overcome this limitation, we developed a platform that produces 2-3 mg of pure BACE2 protein per liter of E. coli culture, and we used this protein to design macrocyclic compounds that potently and selectively inhibit BACE1 over BACE2. Compound 2 was found to potently inhibit BACE 1 (K-i = 5 nM) with a selectivity of 214-fold over BACE2. The X-ray crystal structures of unbound BACE2 (2.2 angstrom) and BACE2 bound to compound 3 (3.0 angstrom and K-i = 7 nM) were determined and compared to the X-ray structures of BACE1 revealing the S1-S3 subsite as a selectivity determinant. This platform should enable a more rapid development of new and selective BACE inhibitors for the treatment of Alzheimer's disease or type II diabetes.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据